- cafead   Oct 24, 2023 at 10:32: AM
via Belgian pharmaceutical company Janssen, a subsidiary of Johnson & Johnson, has reported findings from the Phase III MARIPOSA-2 clinical trial of Rybrevant (amivantamab-vmjw) regimens in locally advanced or metastatic non-small cell lung cancer (NSCLC) patients.
article source
article source